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Abstract. Plasmodium falciparum resistance to the primary drugs used for treatment of malaria has become the main
obstacle to malaria control. Artemisinin combination therapies are the current treatment strategy, and it has been sug-
gested that resistance to artemisinin derivatives may be related to mutations in the Plasmodium falciparum sarcoplasmic-
endoplasmic reticulum Ca2+-ATPase ortholog of the mammalian sarco-endoplasmic reticulum Ca2+ ATPase gene, known
as the pfatp6 gene. Thus, the purpose of this study was to determine the prevalence of single-nucleotide polymorphisms
(SNPs) in pfatp6. The presence of different SNPs was detected by polymerase chain reaction amplification of the pfatp6
gene, and then sequencing to identify all possible alleles of the gene. A total of 20 SNPs were detected, including
eight SNPs that have not been previously described: K481R in Malabo; R801H on Annobon Island; and the synonymous
SNPs a141t, c1788t, a2211g, t2739g, a2760c, and g2836a. The genotypic profile of pfatp6 in samples from Equatorial
Guinea, may be a useful epidemiologic tool for monitoring local efficacy of artemisinin combination therapies.
INTRODUCTION
Half the world’s population is at risk for malaria. The region
most affected by this disease is Africa, accounting for 78% of
the estimated 225 million malaria episodes and 91% of all
malaria-related deaths worldwide in 2009.1 Children less than
five years of age in stable transmission areas, who have not yet
developed protective immunity against the most severe forms
of the disease, constitute a special risk group and have the most
malaria deaths worldwide.2 Equatorial Guinea is an area of
stable malaria transmission, with Plasmodium falciparum being
the most prevalent species: it is not only implicated in more
than 85% of reported cases, but is the main cause of death in
children less than five years of age, accounting for 28% of total
deaths in 2008.3
The spread of antimalarial drug resistance over the past few
decades has led to efficacy monitoring being intensified to
enable early detection of resistance. Since 2006, most countries
to which P. falciparum is endemic have progressively updated
their treatment policies, changing from chloroquine and
sulfadoxine-pyrimethamine (SP) treatments to artemisinin com-
bination therapies (ACTs),whichare recommendedas being the
best current treatment for uncomplicatedP. falciparummalaria.
Unfortunately, there has been a lag in the implementation
of these treatment policies because of various factors, such as
high costs.4 Despite observed changes in parasite sensitivity to
artemisinins (ARTs) in western Cambodia and along the
Thailand-Myanmar border,5–8 the clinical and parasitologic
efficacy of ACTs has not been compromised. However, both
components of the drug combination are currently at risk for
resistance, and using an ART with an ineffective partner
medicine can increase the risk of development and spread of
artemisinin resistance.1
Since 2007, artesunate/amodiaquine has been the first-line
treatment for uncomplicatedP. falciparummalaria inEquatorial
Guinea (National Malaria Control Program). It is proposed
that ARTs lead to parasite death by binding and inhibiting
the P. falciparum sarcoplasmic-endoplasmic reticulum Ca2+-
ATPase ortholog of mammalian sarco-endoplasmic reticulum
Ca2+ ATPase gene, known as PfATP6.9 Recent studies have
focused on PfATP6 structure, and docking simulations suggest
a direct interaction between ARTs and PfATP6, possibly by
hydrophobic interactions.10,11 Additional studies in Xenopus
laevis oocytes with amino acid variants at residue 263 (L263,
263S, and 263A) have shown that Leu263 may modulate sensi-
tivity to ARTs.12
Additional support for PfATP6 as a possible target of ART
compounds in P. falciparum has emerged from a field study,
which reported an association between an S769N substitution
in PfATP6 and elevated in vitro artemether 50% inhibitory
concentrations (IC50s) from French Guiana isolates, sug-
gesting a potential role for polymorphisms at pfatp6 as can-
didate markers for ART resistance emergence.13 This same
study reported one case in Senegal of greatly increased
artemether IC50, which was a PfATPase6 E431K A623E dou-
ble mutant, although each mutation was found alone in other
isolates with no altered parameters. This result is why several
studies have focused on the analysis of known or unknown
single-nucleotide polymorphisms (SNPs) in pfatp6, reporting
on the high diversity of this gene.5,14–24 However, it is believed
that the variability at a single SNP of this gene is insufficient
to induce resistance to ARTs,25 and that any alteration in the
parasite response to artemisinins is probably multigenic and
more complex than it seems, with another candidate being the
multidrug resistance 1 gene.26,27 However, most studies agree
on the importance of continuous screening of pfatp6, with a
view to detecting possible changes in its genotypic pattern as a
response to increasing ACT pressure.
Accordingly, the purpose of this study was to identify the
allelic profile of the PfATPase6 gene in Equatorial Guinea
by using samples collected before the introduction of ACTs
to collect baseline data that would be useful for inferring
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whether the frequency of particular pfatp6 genotypes might
be influenced by treatment in the future.
MATERIALS AND METHODS
Study area. Equatorial Guinea is a country in central Africa
situated in the Gulf of Guinea. It is divided into two regions,
the mainland area between Cameroon and Gabon, known as
Rı́o Muni, and the island area (Bioko, Annobon, Corisco,
Elobey Chico and Elobey Grande) (Figure 1). Bioko, the larg-
est island, is located 40 km from the coast of Cameroon and is
where Malabo, the country’s capital, is located. The climate is
tropical, with a rainy season during May–October and a dry
season during December–March. Bata is the largest city on
the mainland, and has a tropical climate with two dry seasons
(December–March and June–September) alternating with
two rainy seasons (March–June and September–December).
Annobon is a small volcanic island (17 km2), which is located
south of São Tomé and Prı́ncipe, more than 300 miles (approx-
imately 483 km) from the coastline of Gabon and more than
600 miles (approximately 967 km) from the country’s capital
city. The rainy season is from November through April–May
and the dry season is from June through October.
Biological samples. Plasmodium falciparum field isolates
were collected in 2005 as part of an in vivo study conducted
at the Malabo and Bata Regional Hospitals,28 and in 2004
during two cross-sectional studies undertaken on the small
island of Annobon.29 Blood samples were collected from
children les than five years of age with uncomplicated
P. falciparum infections. Diagnosis was carried out by micro-
scopic examination of Giemsa-stained thick blood films. For
each sample, approximately 20 mL of finger prick blood
was spotted on a piece of 3 MM filter paper (Whatman,
Maidstone, United Kingdom) and air-dried. The dried filter
paper samples were stored until DNA extraction for subse-
quent molecular studies.
Extraction of DNA and polymerase chain reaction
amplification. Parasite genomic DNA was extracted from the
filter paper by using a SpeedTools Tissue DNA Extraction Kit
(Biotools B&M Laboratories SA, Madrid, Spain) in accor-
dance with the manufacturer’s instructions. Amplification of
the pfatp6 gene was performed by means of five consecutive
polymerase chain reactions (PCRs), which generated over-
lapping fragments, as described elsewhere.17 Agarose gel elec-
trophoresis was used to ascertain the quality and concentration
of PCR products for each fragment. These fragments were
subsequently purified, where necessary, by using a commer-
cial kit (QIAquick PCR Purification Kit; QIAGEN, Hilden,
Germany) and used as a template for sequencing.
DNA sequencing.DNA sequencing was performed directly
from two independent PCR products for each fragment (for-
ward and reverse) by using the BigDye Terminator version
3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA) and a 3730xlDNAAnalyzer (Applied Biosystems). Sub-
sequent steps were performed with Sequencing Analysis 5.3.1
software, and entailed comparing the sense and antisense
results for each fragment to solve potential ambiguities, and
joining overlapping fragments to obtain the complete gene,
which was aligned with the 3D7 DNA sequence (GenBank
accession no. PFA0310c) to check for genetic polymorphisms.
Ethics. This study was approved by the Ministry of Health
and Welfare of Equatorial Guinea. Written informed consent
was obtained from all adult participants and all parents or
guardians of children.
RESULTS
Of the 55 isolates, a near-full length pfatp6 sequence was
successfully obtained for 48 samples (28–3,078 basepairs).
Because of technical difficulties, we were only able to obtain
the 28–3,078-basepair sequence for 10 of 17 isolates from
Malabo. For the remaining 7 samples, the compiled sequence
spanned nucleotides 28–2,467.
Figure 1. Map of Equatorial Guinea showing the country’s two regions, i.e., the mainland area (Rı́o Muni) and the island area. Map obtained
from http://go.hrw.com/atlas/norm_htm/eqguinea.htm.
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A total of 20 SNPs were detected in Equatorial Guinea, and
9 of these resulted in amino acid substitutions (Table 1). Most
of these substitutions have been found in different locations
throughout Africa,14–16,18,19,24 including the most frequent
and ubiquitous SNPs, such as t1204g (12.7%) and g1291a
(16.4%), which encode the L402V and E431K mutations,
respectively, and the synonymous mutation t2694a (66%). To
our knowledge, however, the following eight SNPs have never
been previously described: a1442g in Malabo and g2402a on
Annobon Island, encoding the amino acid changes K481R
and R801H respectively; and the synonymous a141t, c1788t,
a2211g, t2739g, a2760c, and g2836a SNPs. These novel point
mutations appear to be sporadic, and each was shown to be
confined to a specific geographic region. Neither of the muta-
tions reported as altering susceptibility to artemisinin deriva-
tives, namely L263E and S769N, was found.12,13,30
The number of SNPs grouped by region of origin is shown
in Table 2. On Annobon Island, 10 SNPs were detected, of
which 6 were found at no other site in the country. The most
common SNP was the ubiquitous t2694a, which was present in
14 of 15 samples (Table 1). Five of the polymorphisms were
non-synonymous, and of these polymorphisms, two were
found exclusively on Annobon Island, namely, H243Y, which
had been reported in other parts of Africa,14,18,19 and R801H,
which, to our knowledge, was detected for the first time.
Of the eight SNPs found in Malabo, three were exclusive to
this location and all were non-synonymous (Table 2). The
most common variants were the t2694a SNP, present in 7 of
10 samples; L402V and N569K, both present in 3 of 17 sam-
ples; and E431K, present in 4 of 17 samples. Seven of the
polymorphisms were non-synonymous, and three were loca-
tion-specific: K481R, never previously detected; N569S, pre-
viously reported by our group in Equatorial Guinea24; and
H747Y, previously reported in Africa18 (Table 1).
In Bata, the main city on the mainland, 10 SNPs were
identified, 6 of which (all synonymous) were found nowhere
else in the country (Table 2). Although less prevalent than in
Malabo and Annobon overall, the most common SNP was the
synonymous t2694a, which was present in 12 of 23 samples.
Only three of the polymorphisms were non-synonymous and
none was location-specific. Three synonymous SNPs, located
at residues 596, 737, and 920, had never been previously
described (Table 1).
In addition to the SNPs described above, we also found
two additional genetic variants, in which one or two insertions
of the AAT codon (coding for asparagine: N) adjacent to
residue 465, occurred as follows: two samples, one from
Malabo and another from Bata, displayed the insertion of a
single N at this locus, and one sample from Bata had two N
insertions (Table 3).
The different haplotypes present in the parasite population
were reconstructed by taking all non-synonymous substitu-
tions into account. In doing so, 14 haplotypes were identified,
each occurring at different frequencies (Table 3). Haplotype
number 1, which is the same as that of the reference sequence
of the 3D7 strain of P. falciparum, was the most prevalent
across the study area. Two other haplotypes (2 and 7) that
differing from haplotype 1 in only one SNP, were the next
most frequent, and were found in all regions. Five haplotypes
(3–6 and 8) were exclusive to Malabo, three haplotypes (9–11)
were found exclusively in Bata, and three haplotypes (12–14)
were specific to Annobon.
DISCUSSION
Because there are currently no alternative drugs to replace
artemisinin derivatives in the treatment of uncomplicated
malaria, the emergence and spread of drug-resistant parasite
populations may have disastrous consequences in malaria-
endemic areas. Several studies have reported cases of decreased
in vivo sensitivity to artemisininderivatives inwesternCambodia
and on the Thailand-Myanmar border, where uncontrolled use
of such derivatives has subjected the Plasmodium populations
to strong drug pressure.5–8 Increased in vitro IC50s to the
artemisinin derivative artemether have also been reported in
P. falciparum parasites from French Guiana.13 One interesting
common genetic feature of the French Guiana parasites that
displayed artemether IC50 values > 30 nM was the presence of
an S769N mutation in the pfatp6 gene.13 Interestingly this
S769N mutation is not commonly found in Africa, with the only
exception of an isolate from a patient who referred have trav-
eled to Africa.19 Consequently, this study suggested that pfatp6
genetic variants among natural populations of P. falciparum
may display different responses to artemisinins.
The purpose of this study was to identify genetic variation
in the PfATPase6 gene in three differentiated geographic
areas of Equatorial Guinea and establish a basis for monitor-
ing changes, which may occur over time and may result from
Table 1
Distribution of single-nucleotide polymorphisms, by geographic region,
Equatorial Guinea
Mutations No. mutations Frequency (%)
Nucleotide Amino acid Malabo Bata Annobon Total Total
A141T 47 SYN 0 0 1 1 < 2
C727T H243Y 0 0 1 1 < 2
A945T 315 SYN 0 1 0 1 < 2
T1204G L402V 3 2 2 7 12.7
G1291A E431K 4 3 2 9 16.4
A1320T 440 SYN 0 0 1 1 < 2
A1442G K481R 1 0 0 1 < 2
T1671A 557 SYN 0 1 0 1 < 2
A1706G N569S 1 0 0 1 < 2
T1707A N569K 3 2 0 5 9
C1788T 596 SYN 0 1 0 1 < 2
G1888T A630S 1 0 1 2 3.6
G1927C 643 SYN 0 1 0 1 < 2
A2211G 737 SYN 0 1 0 1 < 2
C2239T H747Y 2 0 0 2 3.6
G2402A R801H 0 0 1 1 < 2
T2694A 898 SYN 7* 12 14 33 66*
T2739G 913 SYN 0* 0 2 2 3.6*
A2760C 920 SYN 0* 1 0 1 < 2*
G2836A 946 SYN 0* 0 1 1 < 2*
*For these mutations and frequency calculations, the fact that in Malabo only 10 samples
have been sequenced has been taken into account.
Table 2








Malabo 17 8 3 7 3
Bata 23 10 6 3 0
Annobon 15 10 6 5 2
*SNPs = single-nucleotide polymorphisms.
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ACT pressure. In addition to Pfatp6 mutations already
described in other areas, eight new point mutations were iden-
tified. These were K481R, R801H and the synonymous SNPs
a141t, c1788t, a2211g, t2739g, a2760c, and g2836a. The pheno-
typic significance of the novel non-synonymous mutations
K481R and R801H is difficult to predict in the absence of
functional studies. Nonetheless, according to a previous predic-
tive model of PfATP6 protein domain architecture,24 the
R801H mutation is in a hydrolase catalytic domain of the pep-
tide, located from residues 790–935. However, whether this
mutation may alter the protein’s function and, consequently,
parasite susceptibility to artemisinins, is unknown.
The PfATP6 E431K variant has been associated with
increased artemether IC50 when found in combination with
mutation A623E in P. falciparum isolates from Senegal.13 In
our study, this mutation was the second most prevalent
(16.4%) because it occurred at every site sampled and was
present in three distinct haplotypes. Howeveer, because the
A623E mutation was not identified in our sample cohort, none
of the haplotypes contained the E431K and A623E mutations
simultaneously. Further analysis will be undertaken to ascer-
tain the influence of mutations on structural variations of pro-
tein, and to relate these changes to in vivo parasite resistance to
artemisinin derivatives.
Before ACT implementation, an in vivo study that had
been conducted locally to evaluate the efficacy of combina-
tion drugs such as AS/SP and AQ/SP, showed that both com-
binations were safe and efficacious as first-line treatments for
treatment for uncomplicated P. falciparum malaria, with a
success rate > 96%.28 Because the samples used for our study
were collected during the same period as for the above in vivo
study, the pfatp6 genotypes identified must be presumed to
represent baseline genetic variation in the gene in the absence
of ART pressure. After five years of using AS/AQ as the first-
line treatment for uncomplicated malaria in Equatorial
Guinea, a new in vivo study is now being conducted to assess
the effectiveness of treatment and, at a molecular level, to
determine the potential effect of ACT treatment on the evo-
lution of PfATP6. It will shortly be possible to verify whether
current treatment pressure has favored the selection of some
of the mutations or whether new SNPs have emerged.
Overall, 20 SNPs and 14 distinct haplotypes were identified
in a cohort of 55 samples. Although these results confirm this
gene’s high genetic diversity, a feature already reported in ear-
lier studies,5,14–21,24 some SNPs were found at low frequencies
andat onlyone location ineach case.Atpresent, the significance
of this high gene diversity inpfatp6 and its potential influence on
the future efficacy ofACTs is largely unknown.However, in the
event that peptide variants of PfATP6 protein might be able to
modulate the parasite’s response to artemisinin derivatives, the
gene’s high genetic diversity would establish a highly favorable
basis for the selection of rare mutants under drug pressure.
Consequently, constant monitoring of pfatp6 genetic variation
and assessment of its potential correlationwith treatmentwould
provide an essential means of assessing the importance of spe-
cific mutations to the evolution ofACT efficacy.
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Table 3
Amino acid haplotypes of the Plasmodium falciparum sarcoplasmic-endoplasmic reticulum Ca2+-ATPase gene and number of samples at each
location, Equatorial Guinea*
Haplotype
Amino acid positions No. samples
243 402 431 – 481 569 630 747 801 Malabo Bata Annobon Total
1 H L E – K N A H R 8 15 9 32
2 . V . – . . . . . 1 1 2 4
3 . . . – . . . Y . 1 1
4 . . K – . K . . . 2 2
5 . . . N- . S . . . 1 1
6 . V . – R K Y . 1 1
7 . . K – . . . . . 2 3 1 6
8 . V . – . . S . . 1 1
9 . V . N- . . . . . 1 1
10 . . . – . K . . . 2 2
11 . . . NN . . . . . 1 1
12 . . K – . . S . . 1 1
13 Y . . – . . . . . 1 1
14 . . . – . . . . H 1 1
Total NA NA NA NA NA NA NA NA NA 17 23 15 55
*Haplotype number 1 corresponds to sequence 3D7 (GenBank accession no. PFA0310c). – = point of insertion of asparagine residues adjacent to position 465; · = sequence identity; NA =
not applicable.
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VE, Póvoa MM, Cravo P, 2008. Plasmodium falciparum
from Para state (Brazil) shows satisfactory in vitro response
to artemisinin derivatives and absence of the S769N muta-
tion in the SERCA-type PfATPase6. Trop Med Int Health 13:
199–207.
22. Mugittu K, Genton B, Mshinda H, Beck HP, 2006. Molec-
ular monitoring of Plasmodium falciparum resistance to
artemisinin in Tanzania. Malar J 5: 126.
23. Zhang G, Guan Y, Zheng B, Wu S, Tang L, 2008. No PfATPase6
S769N mutation found in Plasmodium falciparum isolates from
China. Malar J 7: 122.
24. Jambou R, Martinelli A, Pinto J, Gribaldo S, Legrand E, Niang M,
KimN, Pharath L, Volnay B, EkalaMT, Bouchier C, Fandeur T,
BerzosaP,BenitoA, Ferreira ID,FerreiraC,VieiraPP,Alecrim
MD, Mercereau-Puijalon O, Cravo P, 2010. Geographic struc-
turing of the Plasmodium falciparum sarco(endo)plasmic
reticulum Ca2+ATPase (PfSERCA) gene diversity. PLoS ONE
5: e9424.
25. Cui L, Wang ZL, Jiang HY, Parker D, Wang HY, Su XZ, Cui LW,
2012. Lack of association of the S769N mutation in Plasmodium
falciparum SERCA (PfATP6) with resistance to artemisinins.
AntimicrobAgents Chemother 56: 2546–2552.
26. Duraisingh MT, Cowman AF, 2005. Contribution of the pfmdr1
gene to antimalarial drug-resistance. Acta Trop 94: 181–190.
27. Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP,
Vestergaard LS, Theander TG, Lemnge MM, Bygbjerg IC,
Alifrangis M, 2011. Prevalence of single nucleotide polymor-
phisms in the Plasmodium falciparummultidrug resistance gene
(Pfmdr-1) inKorogweDistrict inTanzaniabefore and after intro-
duction of artemisinin-based combination therapy. Am J Trop
MedHyg 85: 979–983.
28. Charle P, Berzosa P, Descalzo MA, de Lucio A, Raso J, Obono J,
Lwanga M, Nlang N, Nchama A, Mangue C, Micha A, Nsee N,
Mesie R, Benito A, Roche J, 2009. Efficacy of artesunate +
sulphadoxine-pyrimethamine (AS + SP) and amodiaquine +
sulphadoxine-pyrimethamine (AQ + SP) for uncomplicated
falciparummalaria in Equatorial Guinea (central Africa). J Trop
Med 781865. Epub 2009May 27.
29. Cano J, Berzosa P, de Lucio A, Descalzo MA, Bobuakasi L,
Nzambo S, Ondo M, Buatiche JN, Nseng G, Benito A, 2007.
Transmission of malaria and genotypic variability of Plasmo-
dium falciparum on the island of Annobon (Equatorial Guinea).
Malar J 6: 141.
30. Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna
S, 2010. Investigations into the role of thePlasmodium falciparum
SERCA (PfATP6) L263E mutation in artemisinin action and
resistance.AntimicrobAgents Chemother 54: 3842–3852.
PFATP6 MUTATIONS IN EQUATORIAL GUINEA BEFORE ACT 47
